Jiangsu Dahongying Hengshun Pharmaceutical

Jiangsu Dahongying Hengshun Pharmaceutical is a Chinese pharmaceutical company specializing in the development and manufacture of high-quality injectable drugs and solid dosage forms. Founded in 2001 and based in Shuyang, Jiangsu, the company operates GMP-certified facilities producing non-PVC soft bag large volume injections and plastic ampoule small volume injections. Its research and development pipeline, often conducted in partnership with Nanjing Hengdao Pharmaceutical, focuses on ophthalmology, the central nervous system, and cardiovascular health. Key clinical programs include amisulpride for postoperative nausea and vomiting and oxymetazoline for acquired ptosis, both of which are in Phase 3 trials. The company is a joint venture controlled by Hunan Caixin Trust, with strategic participation from the Hengshun Group and Nanjing Hengdao Pharmaceutical. It serves both the domestic Chinese market and international regions including Southeast Asia and South America.